New research indicates that individuals who come off popular slimming jabs like Wegovy and Mounjaro tend to recover lost weight much more quickly than those who halt traditional diet and exercise plans.
Published data in a major health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People purchasing such drugs must be informed of the potential of fast rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.
Such speed of regain implies a return to pre-treatment mass in about one and a half years.
Analyzing Therapies
The analysis, which reviewed dozens of studies involving over 9,000 of participants, compared the results of the injectable medications with older methods.
Scientists emphasize that people who shed pounds through dieting generally see a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts believe the way of the drugs explains the amplified regain.
These medications copy a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the body to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement means hunger is no longer kept in check, making binge eating a significant risk."
A Chronic Condition?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the significant potential of relapse, the treatment should be considered long-term.
This perspective is echoed by drug manufacturers, who note that the results "highlight the persistent character of obesity," akin to managing conditions like diabetes.
Patient Accounts
People who have come off the medication explain a intense resurgence of appetite.
"It was like a trigger that goes on and I was suddenly starving," said one woman.
This difficulty is worsened if patients have not adopted lasting dietary or behavioural changes during therapy.
Growing Use
Survey data indicate that millions of people in the UK have used these injections in the past year, with demand continuing to grow.
- Adoption is higher among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while these medications are powerful tools for shedding pounds, they are not a magic solution and long-term success likely depends on ongoing behavioural management.
